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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to a 
combination of Lactobacillus paracasei CNCM I-1688 and Lactobacillus 
salivarius CNCM I-1794 and reduction of gastro-intestinal discomfort 
(ID 2972), decreasing potentially pathogenic gastro-intestinal 
microorganisms (ID 2972), improved lactose digestion (ID 2972) and 
increasing IL-10 production (ID 2973) (further assessment) pursuant to 
Article 13(1) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies 
(NDA) was asked to provide a scientific opinion on health claims pursuant to Article 13 of Regulation (EC) No 
1924/2006 in the framework of further assessment related to a combination of Lactobacillus paracasei CNCM 
I-1688 and Lactobacillus salivarius CNCM I-1794 and reduction of gastro-intestinal discomfort, decreasing 
potentially pathogenic gastro-intestinal microorganisms, improved lactose digestion and increasing IL-10 
production. The food constituent that is the subject of the health claims, a combination of L. paracasei CNCM 
I-1688 and L. salivarius CNCM I-1794, is sufficiently characterised. The evidence provided did not establish 
that the proposed claimed effect, increasing IL-10 production, is a beneficial physiological effect. On the basis 
of the data presented, the Panel concludes that a cause and effect relationship has not been established between 
the consumption of a combination of L. paracasei CNCM I-1688 and L. salivarius CNCM I-1794 and a 
beneficial physiological effect related to an increase in IL-10 production. The claimed effect, reduction of 
gastro-intestinal discomfort, is a beneficial physiological effect for the general population. The claimed effect, 
decreasing potentially pathogenic gastro-intestinal microorganisms, might be a beneficial physiological effect 
for the general population. The claimed effect, improved lactose digestion, is a beneficial physiological effect 
for individuals with lactose maldigestion. No human intervention studies were provided from which 
conclusions could be drawn for the scientific substantiation of the above-mentioned claims. On the basis of the 
data provided, the Panel concludes that a cause and effect relationship has not been established between the 
consumption of a combination of L. paracasei CNCM I-1688 and L. salivarius CNCM I-1794 and reduction of 
gastro-intestinal discomfort, decreasing potentially pathogenic gastro-intestinal microorganisms and improved 
lactose digestion. © European Food Safety Authority, 2012 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2012-00200, EFSA-Q-2012-00201, adopted on 
28 June 2012. 
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Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge 
Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
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SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to provide a scientific opinion on a list of health claims pursuant to 
Article 13 of Regulation (EC) No 1924/2006. The Commission has agreed with EU Member States 
that a certain number of Article 13 health claims would be eligible for further assessment by EFSA 
in order to be able to take a final decision on whether or not to include these claims in the list of 
permitted health claims. This opinion addresses the scientific substantiation of health claims in 
relation to a combination of Lactobacillus paracasei CNCM I-1688 and Lactobacillus salivarius 
CNCM I-1794 and reduction of gastro-intestinal discomfort, decreasing potentially pathogenic 
gastro-intestinal microorganisms, improved lactose digestion and increasing IL-10 production. The 
scientific substantiation is based on the information provided by the competent Authority of Italy for 
further assessment of this claim.  
The food constituent that is the subject of the health claims is a combination of L. paracasei CNCM 
I-1688 and L. salivarius CNCM I-1794. The Panel considers that the combination of L. paracasei 
CNCM I-1688 and L. salivarius CNCM I-1794 is sufficiently characterised.  
Reduction of gastro-intestinal discomfort 
The claimed effect which is proposed for further assessment relates to reduction of gastro-intestinal 
discomfort. The proposed target population is the general population. Reduction of gastro-intestinal 
discomfort is a beneficial physiological effect. 
No human intervention studies were provided from which conclusions could be drawn for the 
scientific substantiation of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of a combination of L. paracasei CNCM I-1688 and 
L. salivarius CNCM I-1794 and reduction of gastro-intestinal discomfort. 
Decreasing potentially pathogenic gastro-intestinal microorganisms  
The claimed effect which is proposed for further assessment relates to a decrease in potentially 
pathogenic gastro-intestinal microorganisms. The proposed target population is the general 
population. Decreasing potentially pathogenic gastro-intestinal microorganisms might be a beneficial 
physiological effect. 
No human intervention studies were provided from which conclusions could be drawn for the 
scientific substantiation of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of a combination of L. paracasei CNCM I-1688 and 
L. salivarius CNCM I-1794 and decreasing potentially pathogenic gastro-intestinal microorganisms. 
Improved lactose digestion  
The claimed effect which is proposed for further assessment relates to improved lactose digestion. 
Improved lactose digestion is a beneficial physiological effect for individuals with lactose 
maldigestion. 
No human intervention studies were provided from which conclusions could be drawn for the 
scientific substantiation of the claim. 
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On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of a combination of L. paracasei CNCM I-1688 and 
L. salivarius CNCM I-1794 and improved lactose digestion. 
Increasing IL-10 production 
The claimed effect which is proposed for further assessment relates to increasing IL-10 production. 
The proposed target population is the general population. The Panel notes that increasing IL-10 
production by peripheral blood mononuclear cells is not a beneficial physiological effect per se, but 
needs to be linked to a beneficial physiological or clinical outcome.  
The Panel considers that the evidence provided did not establish that increasing IL-10 production is a 
beneficial physiological effect. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of a combination of L. paracasei CNCM I-1688 and 
L. salivarius CNCM I-1794 and a beneficial physiological effect related to an increase in IL-10 
production. 
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INTRODUCTION 
The Commission has agreed with EU Member States that a certain number of Article 13 health 
claims would be eligible for further assessment by EFSA in order to be able to take a final decision 
on whether or not to include these claims in the list of permitted health claims. These claims include 
already assessed claims related to micro-organisms which the Panel considered to be not sufficiently 
characterised and claims for which the NDA Panel concluded that there was insufficient evidence to 
establish a cause and effect relationship between the consumption of the food and the claimed effect. 
Following an opinion of the NDA Panel pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 in 
which the Panel concluded that the data available were not sufficient to characterise a combination of 
Lactobacillus paracasei I-1688 and Lactobacillus salivarius I-1794 (EFSA Panel on Dietetic 
Products Nutrition and Allergies (NDA), 2009), EFSA received additional information from the 
competent Authority of Italy for further assessment of this claim. The information provided in the 
framework of further assessment for the health claims which are the subject of this opinion is 
tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent  
The food constituent that is the subject of the health claim is a combination of Lactobacillus 
paracasei CNCM I-1688 and Lactobacillus salivarius CNCM I-1794. 
For L. paracasei CNCM I-1688, a culture collection number from the French National Collection of 
Cultures of Microorganisms (CNCM) (I-1688) was provided. The CNCM is a restricted-access 
non-public collection which has the status of an International Depositary Authority under the 
Budapest Treaty. Data on the identification and characterisation of L. paracasei CNCM I-1688 at 
species and strain level, by using both phenotypic (carbohydrate fermentation profiles) and genotypic 
(16S rRNA gene sequence analysis, plasmidic profile, ARDRA, RAPD, Rep-PCR, PFGE) methods, 
were provided in the applications for further assessment and in the accompanying references (AAT, 
2011a, unpublished; Bonetti et al., 2002; Morelli, 1996, unpublished; Morelli, 1997, unpublished; 
Pedraglio, 2004). The Panel considers that L. paracasei CNCM I-1688 is sufficiently characterised. 
For L. salivarius CNCM I-1794, a culture collection number from the CNCM, I-1794, was provided. 
Data on the identification and characterisation of L. salivarius CNCM I-1794 at species and strain 
level, by using both phenotypic (carbohydrate fermentation profiles) and genotypic (16S rRNA gene 
sequence analysis, plasmidic profile, ARDRA, RAPD, Rep-PCR, PFGE) methods, were provided in 
the applications for further assessment and in the accompanying references (AAT, 2011b, 
unpublished; Bonetti et al., 2002; Morelli, 1996, unpublished; Morelli, 1997, unpublished; Pedraglio, 
2004). The Panel considers that L. salivarius CNCM I-1794 is sufficiently characterised. 
The Panel considers that the food constituent, the combination of L. paracasei CNCM I-1688 and 
L. salivarius CNCM I-1794, is sufficiently characterised. 
2. Relevance of the claimed effect to human health 
2.1. Reduction of gastro-intestinal discomfort (ID 2972) 
The claimed effect which is proposed for further assessment is: “Is a probiotic; Contributes to a 
healthy digestive system by supporting the gut flora through an increased number of positive 
lactobacillus in the intestine; useful to maintain a healthy intestinal flora by adhering to the mucosa; 
Improves intestinal barrier function by competing (steric encumbrance) against pathogens; Reduces 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
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gastro-intestinal discomfort; Necessary to maintain a healthy digestive system by production of 
specific enzymes (eg: beta-galactosidase)”. The proposed target population is the general population. 
The Panel considers that reduction of gastro-intestinal discomfort is a beneficial physiological effect. 
2.2. Decreasing potentially pathogenic gastro-intestinal microorganisms (ID 2972) 
The claimed effect which is proposed for further assessment is: “Is a probiotic; Contributes to a 
healthy digestive system by supporting the gut flora through an increased number of positive 
lactobacillus in the intestine; useful to maintain a healthy intestinal flora by adhering to the mucosa; 
Improves intestinal barrier function by competing (steric encumbrance) against pathogens; Reduces 
gastro-intestinal discomfort; Necessary to maintain a healthy digestive system by production of 
specific enzymes (eg: beta-galactosidase)”. The proposed target population is the general population. 
The Panel notes that it is not possible to define the exact number of the different microbial groups 
which constitute a normal/healthy microbiota. Increasing the number of any groups of 
microorganisms, including lactobacilli, is not in itself considered to be a beneficial physiological 
effect.  
The Panel assumes that the claimed effect refers to decreasing potentially pathogenic gastro-
intestinal microorganisms. The Panel considers that decreasing potentially pathogenic gastro-
intestinal microorganisms might be a beneficial physiological effect. 
2.3. Improved lactose digestion (ID 2972) 
The claimed effect which is proposed for further assessment is: “Is a probiotic; Contributes to a 
healthy digestive system by supporting the gut flora through an increased number of positive 
lactobacillus in the intestine; useful to maintain a healthy intestinal flora by adhering to the mucosa; 
Improves intestinal barrier function by competing (steric encumbrance) against pathogens; Reduces 
gastro-intestinal discomfort; Necessary to maintain a healthy digestive system by production of 
specific enzymes (eg: beta-galactosidase)”. The proposed target population is the general population. 
The Panel assumes that the claimed effect refers to improved lactose digestion, and that the target 
population is individuals with lactose maldigestion. Lactose maldigestion is a common condition 
caused by reduced levels of intestinal lactase.   
The Panel considers that improved lactose digestion is a beneficial physiological effect for 
individuals with lactose maldigestion 
2.4. Increasing IL-10 production (ID 2973) 
The claimed effect which is proposed for further assessment is: “Supports your natural (immune) 
defence system by increasing the IL-10 production in peripheral blood mononuclear cells (PBMC); 
Necessary to maintain the natural defences/helps to maintain a balanced immune system (increasing 
the IL-10 production)”. The proposed target population is the general population. 
The Panel notes that the claimed effect “supports your natural (immune) defence system /necessary 
to maintain the natural defences/helps to maintain a balanced immune system” is not sufficiently 
defined, and assumes that the claimed effect relates to increasing IL-10 production by peripheral 
blood mononuclear cells. The Panel notes that increasing IL-10 production by peripheral blood 
mononuclear cells is not a beneficial physiological effect per se, but needs to be linked to a 
beneficial physiological or clinical outcome. 
The references provided in relation to the claim were related to the methodology for bacterial strain 
identification, in vitro studies on the immunomodulatory properties of the combination of the strains 
(i.e. phenotype of the lymphocytic subpopulations, and cytokine production such as IL-10, IL-12, 
INFγ; (Castellazzi et al., 2007; Castellazzi, 2007a, unpublished)), and a patent (Dondi and Malfa, 
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2007) which reported on the use of the lactic bacteria that are the subject of the claim for the 
preparation of a composition suitable for modulating the immune system, and also on the in vitro 
effects of the strains on lymphocytes (lymphocyte proliferation, phenotype of the lymphocytic 
subpopulations, and cytokine production), but without providing primary data. Two references 
reported on the same human intervention study (Castellazzi, 2007a, unpublished; Valsecchi et al., 
2008), which was an open-label, single arm (non-placebo controlled) study which investigated the 
effects of a combination of L. paracasei CNCM I-1688 and L. salivarius CNCM I-1794 on 
symptoms of allergy (atopic dermatitis, rhino-conjunctivitis, urticaria, contact dermatitis, oral allergy 
syndrome and food allergies), and on immunological parameters (e.g. lymphocyte population, 
natural killer cell activity and cytokine production), in 20 children with atopic disorders. The Panel 
notes that this study was a single-arm study with no control group, and considers that no conclusions 
can be drawn from this study for the scientific substantiation of the claim. 
The Panel considers that the evidence provided does not establish that increasing IL-10 production 
by peripheral blood mononuclear cells is a beneficial physiological effect. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of a combination of L. paracasei CNCM I-1688 and L. salivarius CNCM I-1794 and a 
beneficial physiological effect related to an increase in IL-10 production. 
3. Scientific substantiation of the claimed effect 
3.1. Reduction of gastro-intestinal discomfort (ID 2972) 
The references provided in relation to this claim were related to methodologies for bacterial strain 
identification (Jensen et al., 1993; Ventura et al., 2000); patents for the use of two Lactobacillus 
strains (L. gasseri P-17632 and/or L. salivarius CNCM I-1794) other than the combination that is the 
subject of the claim against Candida albicans (Dondi, 2004, 2007); a patent on a method for the 
selection of Lactobacillus strains, including L. paracasei CNCM I-1688 and L. salivarius CNCM 
I-1794, indicated to be useful for the treatment of various disorders of the gastro-intestinal tract 
because of their capability to produce lactic acid (Pedraglio, 2004); and a human intervention study 
on the viability of the combination of the strains that is the subject of the claim through the human 
intestinal tract (Bonetti et al., 2002). The Panel notes that these studies did not address outcome 
measures related to the claimed effect, and considers that no conclusions can be drawn from these 
references for the scientific substantiation of the claim. 
The Panel notes that no human studies were provided from which conclusions could be drawn for the 
scientific substantiation of the claim. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the combination of L. paracasei CNCM I-1688 and L. salivarius CNCM I-1794 and 
reduction of gastro-intestinal discomfort.  
3.2. Decreasing potentially pathogenic gastro-intestinal microorganisms (ID 2972) 
The references provided in relation to this claim were related to methodologies for bacterial strain 
identification (Jensen et al., 1993; Ventura et al., 2000); a patent on a method for the selection of 
Lactobacillus strains, including L. paracasei CNCM I-1688 and L. salivarius CNCM I-1794, 
indicated to be useful for the treatment of various disorders of the gastro-intestinal tract because of 
their capability to produce lactic acid (Pedraglio, 2004); and a human intervention study on the 
viability of the combination of the strains that is the subject of the claim through the human intestinal 
tract (Bonetti et al., 2002). The Panel notes that these studies did not address outcome measures 
related to the claimed effect, and considers that no conclusions can be drawn from these references 
for the scientific substantiation of the claim. 
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Two patents for the use of L. gasseri P-17632 and/or L. salivarius CNCM I-1794 against Candida 
albicans (Dondi, 2004, 2007) were also provided. The Panel notes that only one of the strains 
mentioned in the patents is part of the combination of strains that is the subject of the claim, and that 
no primary data were provided that could be used for the substantiation of the claim. The Panel 
considers that no conclusions can be drawn from these patents for the scientific substantiation of the 
claim. 
The Panel notes that no human studies were provided from which conclusions could be drawn for the 
scientific substantiation of the claim. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the combination of L. paracasei CNCM I-1688 and L. salivarius CNCM I-1794 and 
decreasing potentially pathogenic gastro-intestinal microorganisms.  
3.3. Improved lactose digestion (ID 2972) 
The references provided in relation to this claim were related to methodologies for bacterial strain 
identification (Jensen et al., 1993; Ventura et al., 2000); patents for the use against Candida albicans 
of two Lactobacillus strains (Lactobacillus gasseri P-17632 and/or L. salivarius CNCM I-1794) 
other than the combination that is the subject of the claim (Dondi, 2004, 2007); a patent on a method 
for the selection of Lactobacillus strains, including L. paracasei CNCM I-1688 and L. salivarius 
CNCM I-1794, indicated to be useful for the treatment of various disorders of the gastro-intestinal 
tract because of their capability to produce lactic acid (Pedraglio, 2004); and a human intervention 
study on the viability of the combination of the strains hat is the subject of the claim through the 
human intestinal tract (Bonetti et al., 2002). The Panel notes that these studies did not address 
outcome measures related to the claimed effect, and considers that no conclusions can be drawn from 
these references for the scientific substantiation of the claim. 
The Panel notes that no human studies were provided from which conclusions could be drawn for the 
scientific substantiation of the claim. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of a combination of L. paracasei CNCM I-1688 and L. salivarius CNCM I-1794 and 
improved lactose digestion.  
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, a combination of L. paracasei CNCM I-1688 and L. salivarius CNCM 
I-1794, which is the subject of the health claims, is sufficiently characterised. 
Reduction of gastro-intestinal discomfort (ID 2972) 
 The claimed effect proposed for further assessment relates to reduction of gastro-intestinal 
discomfort. The proposed target population is the general population. Reduction of 
gastro-intestinal discomfort is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of a 
combination of L. paracasei CNCM I-1688 and L. salivarius CNCM I-1794 and reduction of 
gastro-intestinal discomfort. 
Decreasing potentially pathogenic gastro-intestinal microorganisms (ID 2972) 
 The claimed effect proposed for further assessment relates to a decrease in potentially 
pathogenic gastro-intestinal microorganisms. The proposed target population is the general 
Health claims related to a combination of L. paracasei CNCM I-1688  
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population. Decreasing potentially pathogenic gastro-intestinal microorganisms might be a 
beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of a 
combination of L. paracasei CNCM I-1688 and L. salivarius CNCM I-1794 and decreasing 
potentially pathogenic gastro-intestinal microorganisms. 
Improved lactose digestion (ID 2972) 
 The claimed effect proposed for further assessment relates to improved lactose digestion. 
Improved lactose digestion is a beneficial physiological effect for individuals with lactose 
maldigestion. 
 A cause and effect relationship has not been established between the consumption of a 
combination of L. paracasei CNCM I-1688 and L. salivarius CNCM I-1794 and improved 
lactose digestion. 
Increasing IL-10 production (ID 2973) 
 The claimed effect proposed for further assessment relates to increasing IL-10 production. 
The proposed target population is the general population. The evidence provided did not 
establish that increasing IL-10 production is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of a 
combination of L. paracasei CNCM I-1688 and L. salivarius CNCM I-1794 and a beneficial 
physiological effect related to an increase in IL-10 production. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 for further assessment 
(No: EFSA-Q-2012-00200 and EFSA-Q-2012-00201). The scientific substantiation is based on the 
information provided by the competent Authority of Italy for further assessment of this claim 
(available on: http://www.efsa.europa.eu/en/topics/topic/article13.htm). 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
5
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
6
  
Foods are commonly involved in many different functions
7
 of the body, and for one single food 
many health claims may therefore be scientifically true. Therefore, the relative importance of food 
e.g. nutrients in relation to other nutrients for the expressed beneficial effect should be considered: 
for functions affected by a large number of dietary factors it should be considered whether a 
reference to a single food is scientifically pertinent.  
It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
                                                     
5  OJ L12, 18/01/2007 
6  The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
7  The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. 
Claims should be scientifically substantiated by taking into account the totality of the available 
scientific data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and 
the claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of 
the target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional 
or physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment 
whether such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between 
the food and the function. This may be due to commercial practices, consumer perception and 
linguistic or cultural differences across the EU. Nevertheless, the wording used to make health 
claims should be truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement 
to describe or refer to the 'role' of a nutrient or substance in growth, development and the functions 
of the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
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The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different 
relationships between the various foods and health. It is not the intention of the regulator to adopt a 
detailed and rigid list of claims where all possible wordings for the different claims are approved. 
Therefore, it is not required that EFSA comments on each individual wording for each claim unless 
the wording is strictly pertinent to a specific claim. It would be appreciated though that EFSA may 
consider and comment generally on such elements relating to wording to ensure the compliance with 
the criteria laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific 
data, and by weighing the evidence. In this context EFSA is invited to comment on the 
nature and quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and 
the claimed effect in humans and whether the magnitude of the effect is related to the 
quantity consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
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 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the 
marketing of the food/food constituent, a positive assessment of its safety, nor a decision on whether 
the food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an 
assessment is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions 
of use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Health claims related to a combination of Lactobacillus paracasei CNCM I-1688 and 
Lactobacillus salivarius CNCM I-1794 including conditions of use, as proposed in the framework of 
further assessment. 
ID Food or Food constituent Health Relationship Proposed wording 
2972 PSMIX®: mixture of 
Lactobacillus paracasei 
CNCM I 1688 and 
Lactobacillus salivarius 
CNCM I 1794. 
Is a probiotic;  
Contributes to a healthy 
digestive system by supporting 
the gut flora through an 
increased number of positive 
lactobacillus in the intestine;  
useful to maintain a healthy 
intestinal flora by adhering to 
the mucosa;  
Improves intestinal barrier 
function by competing (steric 
encumbrance) against 
pathogens;  
Reduces gastro-intestinal 
discomfort;  
Necessary to maintain a 
healthy digestive system by 
production of specific 
enzymes (eg: 
betagalactosidase). 
PSMIX® is a probiotic 
mixture that maintains the 
balance of healthy intestinal 
microflora and regulates 
intestinal functionality by 
replacing normal, natural 
microflora (especially after 
antibiotic/antimycotic 
treatment) which contributes 
to reducing gastro-intestinal 
discomfort which, for 
example, could be due to 
problems in lactose 
digestion. 
Conditions of use 
Being 'Generally Recognized as Safe' (GRAS) by the Food and Drug Administration, this health 
claim is destined for the general population. 
The advised condition of use of this constituent is of at least 1x10
9
 ufc per day. 
Since this product's release on the market, there have not been any reported cases of undesirable 
side effects due to this nutrient, however, italian national law imposes the use of these 
precautions on the product label: Do not exceed the indicated dosage; Keep out of reach of 
children under three years of age; The intake of this supplement is not meant as a substitute to a 
balanced diet and healthy lifestyle. 
This product is presented in a soluble powder form. Dissolve the content of one sachet in water 
or warm milk, and drink immediately. Should be consumed, preferably, on an empty stomach. 
ID Food or Food constituent Health Relationship Proposed wording 
2973 PSMIX® : mixture of 
Lactobacillus paracasei 
CNCM I 1688 and 
Lactobacillus salivarius 
CNCM I 1794.  
Supports your natural 
(immune) defence system by 
increasing the IL-10 
production in peripheral blood 
mononuclear cells (PBMC); 
As recommended by 
PASSCLAIM, the functional 
capacity of the immune system 
has been assessed by: 
measuring specific cell 
functions ex vivo, measuring 
specific cell function in vivo 
e.g. production of cytokines or 
PSMIX® is a probiotic 
mixture that helps to support 
natural defences by 
modulating natural 
immunological responses, 
and helps to support the 
development of the immune 
system by regulating an 
immunological response in 
subjects with allergic 
reactions or by stimulating 
immunological response 
during viral infections. 
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response to antigens, and 
determining the incidence and 
severity of infection; 
Necessary to maintain the 
natural defences/helps to 
maintain a balanced immune 
system (increasing the IL-10 
production). 
Conditions of use 
Being 'Generally Recognized as Safe' (GRAS) by the Food and Drug Administration, this health 
claim is destined for the general population. 
The advised condition of use of this constituent is of at least 1x109 ufc per day. 
Since this product's release on the market, there have not been any reported cases of undesirable 
side effects due to this nutrient, however, italian national law imposes the use of these 
precautions on the product label: Do not exceed the indicated dosage; Keep out of reach of 
children under three years of age; The intake of this supplement is not meant as a substitute to a 
balanced diet and healthy lifestyle. 
This product is presented in a soluble powder form. Dissolve the content of one sachet in water 
or warm milk, and drink immediately. Should be consumed, preferably, on an empty stomach. 
Health claims related to a combination of L. paracasei CNCM I-1688  
and L. salivarius CNCM I-1794 (further assessment) 
 
20 EFSA Journal 2012;10(8):2856 
GLOSSARY AND ABBREVIATIONS 
ARDRA Amplified rDNA restriction analysis 
CNCM  Collection Nationale de Cultures de Microorganismes, France  
DNA  Deoxyribonucleic acid  
PCR  Polymerase chain reaction 
PFGE  Pulsed field gel electrophoresis 
RAPD  Randomly amplified polymorphic DNA 
Rep-PCR Repetitive extragenomic palindromic – PCR 
RNA  Ribonucleic acid  
